Eficacy and safety of pegylated interferon-α2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B

Antiviral Therapy

Volumn 18, Issue 6, 2013, Pages 765-773

  Suh, Dong Jin ^a   Lee, Han Chu ^a   Byun, Kwan Soo ^b   Cho, Mong ^c   Kweon, Young Oh ^d   Tak, Won Young ^d   Chon, Chae Yoon ^e   Koh, Kwang Cheol ^f   Lee, Young Sok ^g  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d Kyungpook National University Hospital   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; VIRUS DNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; UPPER RESPIRATORY TRACT INFECTION; VIRUS INHIBITION; ANTIVIRAL RESISTANCE; BLOOD; CLINICAL TRIAL; HEPATITIS B, CHRONIC; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84892378232     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2664     Document Type: Article

References (34)

1. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008; 2:147-151
2. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t) ide analogues. Gastroenterology 2009; 137:1593-1608
3. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36:687-696
4. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Paciic consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol Int 2012; 6:531-561
5. Marcellin P, Sung J, Piratvisuth T. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Liver Int 2010; 30:657-668
6. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleosidenaive patients is rare through 5 years of therapy. Hepatology 2009; 49:1503-1514
7. Tenney DJ, Pokornowski KA, Rose RE, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. J Hepatol 2009; 50:S10
8. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43:1385-1391
9. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45:307-313
10. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55:1488-1495
11. Toyama T, Ishida H, Ishibashi H, et al. Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B. Hepatol Res 2012; 42:1168-1174
12. European Association for the Study of the Liver. EASL Clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-185
13. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662
14. Marcellin P, Boyer N, Piratvisuth T, et al. Eficacy and safety of peginterferon alpha-2a (40KD) (Pegasys) in patients with chronic hepatitis B who had received prior treatment with nucleos(t)ide analogues - the PEGALAM cohort. J Hepatol 2006; 44:S187
15. Xu DZ, Xie Y, Wei L, et al. Eficacy and safety of peginterferon alfa-2a in Chinese patients with HBeAgpositive chronic hepatitis B. J Hepatol 2008; 48:S266
16. Sun J, Hou JL, Xie Q, et al. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. Aliment Pharmacol Ther 2011; 34:424-431
17. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695
18. Leemans WF, Flink HJ, Janssen HL, Niesters HG, Schalm SW, de Man RA. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection. J Hepatol 2006; 44:507-511
19. Vassiliadis T, Patsiaoura K, Tziomalos K, et al. Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2006; 12:2417-2422
20. Hou J, Sun J, Xie Q, et al. Eficacy and safety of peginterferon alfa-2a versus adefovir dipivoxil (ADV) in treating lamivudine resistant HBeAg positive CHB: an interim analysis of a prospective randomized study. Hepatology 2008; 48:745A
21. Hong SP, Kim NK, Hwang SG, et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004; 40:837-844
22. Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study. J Hepatol 2009; 50:1084-1092
23. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39:804-810
24. Fattovich G, Giustina G, Sanchez-Tapias J, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 1998; 93:896-900
25. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 2005; 365:123-129
26. Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011; 54:1591-1599
27. Cha CH, Sohn YH, Ko SY, Oh HB. [Subgenotype and serotype analysis of hepatitis B virus in Korean chronic hepatitis B patients under treatment]. Korean J Lab Med 2009; 29:53-58. Korean
28. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36:1425-1430
29. Flink HJ, van zonneveld M, Hansen BE, et al. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101:297-303
30. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011; 26:123-130
31. ter Borg MJ, Hansen BE, Bigot G, Haagmans BL, Janssen HL. ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B. J Clin Virol 2008; 42:160-164
32. Liaw YF. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antivir Ther 2009; 14:13-22
33. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAgpositive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135:459-467
34. Wong VW, Wong GL, Yan KK, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51:1945-1953